Cato Research Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Durham NC United States (1988)

Organization Overview

First Clinical Trial
1993
NCT02181465
First Marketed Drug
2010
hexyl 5-aminolevulinate (Cysview)
First NDA Approval
2010
hexyl 5-aminolevulinate (Cysview)
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Cancer Advances Inc. | Cato Research | CATO-SMS